Company Profile For Cardiome Pharma Corp.

Cardiome Pharma Corp. (Cardiome) is a life sciences company focused on developing drugs to treat or prevent cardiovascular diseases. The Company’s drug development efforts are focused on the treatment of atrial arrhythmias, a Phase I program for GED-aPC, an engineered analog of human activated protein C, and a pre-clinical program directed at improving cardiovascular function. As of December 31, 2008, Cardiome had five wholly owned subsidiaries: Rhythm-Search Developments Ltd., Cardiome, Inc., Artesian, Cardiome Development AG, and Cardiome UK Limited. On February 28, 2009, its wholly owned subsidiary Cardiome Research and Development (Barbados), Inc., a company incorporated under the Companies Act of Barbados, was continued into Canada under the Canada Business Corporations Act and was amalgamated with Cardiome Pharma Corp. on March 1, 2009.

BRIEF: For the six months ended 30 June 2009, Cardiome Pharma Corp.'s revenues totaled C$8.8M, up from C$658K. Net loss decreased 67% to C$13.5M. Revenues reflect an increase in licensing fees and higher research collaborative fees. Lower loss was partially offset by an increase in general & administrative expenses and lower interest & other income. The company is in drug research & development.